Ironwood Pharmaceuticals
Founded Year
1998Stage
IPO | IPOTotal Raised
$307.3MDate of IPO
2/12/2010Market Cap
1.62BStock Price
10.35About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is a gastrointestinal (GI) healthcare company. It offers LINZESS, a therapeutic drug for the treatment of irritable bowel syndrome. It was founded in 1998 and is based in Boston, Massachusetts.
Loading...
Loading...
Ironwood Pharmaceuticals Patents
Ironwood Pharmaceuticals has filed 123 patents.
The 3 most popular patent topics include:
- gastrointestinal tract disorders
- diseases of intestines
- gastroenterology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/6/2017 | 1/12/2021 | Dosage forms, Pharmaceutical industry, Pharmacokinetics, Drug delivery devices, Amines | Grant |
Application Date | 7/6/2017 |
|---|---|
Grant Date | 1/12/2021 |
Title | |
Related Topics | Dosage forms, Pharmaceutical industry, Pharmacokinetics, Drug delivery devices, Amines |
Status | Grant |
Latest Ironwood Pharmaceuticals News
Nov 23, 2023
根据最近向美国证券交易委员会提交的 13F 表格，信安金融集团公司 (Principal Financial […]
Ironwood Pharmaceuticals Frequently Asked Questions (FAQ)
When was Ironwood Pharmaceuticals founded?
Ironwood Pharmaceuticals was founded in 1998.
Where is Ironwood Pharmaceuticals's headquarters?
Ironwood Pharmaceuticals's headquarters is located at 100 Summer Street, Boston.
What is Ironwood Pharmaceuticals's latest funding round?
Ironwood Pharmaceuticals's latest funding round is IPO.
How much did Ironwood Pharmaceuticals raise?
Ironwood Pharmaceuticals raised a total of $307.3M.
Who are the investors of Ironwood Pharmaceuticals?
Investors of Ironwood Pharmaceuticals include Astellas Venture Management, Venrock, Polaris Partners, F-Prime Capital, Fidelity Investments and 16 more.
Who are Ironwood Pharmaceuticals's competitors?
Competitors of Ironwood Pharmaceuticals include Vitae Pharmaceuticals, Creative Biomolecules, Cara Therapeutics, AI2, Parabolic Drugs and 7 more.
Loading...
Compare Ironwood Pharmaceuticals to Competitors
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Neuronyx is focused on developing biomedicines by harnessing the therapeutic potential of the human cell.
Resolvyx Pharmaceuticals offers CombinatoRx which is creating new combination medicines that attack disease on multiple fronts
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
OcuNexus Therapeutics is a clinical-stage company focused on the healthcare sector, specifically in the development of treatments for diseases where the inflammasome pathway of inflammation is dysregulated. The company's main product is a small molecule, administered orally once a day, that targets the pathologically open Connexin43 Hemichannel, which is responsible for inflammasome mediated autoinflammation in several disease states. The company primarily sells to the ophthalmology and nephrology sectors, with a focus on conditions such as diabetic retinopathy, diabetic nephropathy, and the intermediate stage of macular degeneration. OcuNexus Therapeutics was formerly known as CoDa Therapeutics. It was founded in 2005 and is based in San Diego, California.
ASC Therapeutic is a privately-held gene therapy company focused on developing transformative gene-based medicines for serious diseases.
Loading...